Ellagic acid improves hepatic steatosis and serum lipid composition through reduction of serum resistin levels and transcriptional activation of hepatic ppara in obese, diabetic KK-Ay mice

Biochemical and Biophysical Research Communications

Volumn 434, Issue 3, 2013, Pages 486-491

  Yoshimura, Yukihiro ^a   Nishii, Saori ^a   Zaima, Nobuhiro ^a   Moriyama, Tatsuya ^a   Kawamura, Yukio ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

Adipocytokine; Ellagic acid; Metabolic syndrome; Obese; ppara; Resistin

Indexed keywords

ADIPOCYTOKINE; ELLAGIC ACID; LIPID; MESSENGER RNA; RESISTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RETN PROTEIN, MOUSE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOA1 GENE; ARTICLE; CONTROLLED STUDY; CPT1A GENE; DYSLIPIDEMIA; FATTY LIVER; GENE; GENE EXPRESSION REGULATION; LDLR GENE; LIPID BLOOD LEVEL; LIPID COMPOSITION; MALE; MOUSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PPARA GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSCRIPTION INITIATION; UPREGULATION; ANIMAL; BLOOD; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; MOUSE MUTANT;

LYTHRACEAE; MURINAE; MUS;

ANIMALS; ELLAGIC ACID; FATTY LIVER; LIPIDS; MICE; MICE, MUTANT STRAINS; OBESITY; PPAR ALPHA; RESISTIN; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

MLCS; MLOWN;

EID: 84880452123     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.03.100     Document Type: Article

References (34)

1. M.P. Reilly, D.J. Rader, The metabolic syndrome - more than the sum of its parts?, Circulation 108 (2003) 1546-1551
2. S.M. Grundy, Obesity, metabolic syndrome, and cardiovascular disease, J. Clin. Endocrinol. Metab. 89 (2004) 2595-2600.
3. Y. Matsuzawa, The metabolic syndrome and adipocytokines, FEBS Lett. 580 (2006) 2917-2921.
4. E. Maury, S.M. Brichard, Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome, Mol. Cell. Endocrinol. 314 (2010) 1-16.
5. K. Tomita, Y. Oike, T. Teratani, T. Taguchi, M. Noguchi, T. Suzuki, A. Mizutani, H. Yokoyama, R. Irie, H. Sumimoto, A. Takayanagi, K. Miyashita, M. Akao, M. Tabata, G. Tamiya, T. Ohkura, T. Hibi, Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice, Hepatology 48 (2008) 458-473.
6. T. Masaki, S. Chiba, H. Tatsukawa, T. Yasuda, H. Noguchi, M. Seike, H. Yoshimatsu, Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice, Hepatology 40 (2004) 177-184.
7. A. Baranova, S.J. Gowder, K. Schlauch, H. Elariny, R. Collantes, A. Afendy, J.P. Ong, Z. Goodman, V. Chandhoke, Z.M. Younossi, Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance, Obes. Surg. 16 (2006) 1118-1125.
8. Y. Ogawa, T. Kikuchi, K. Nagasaki, M. Hiura, Y. Tanaka, M. Uchiyama, Usefulness of serum adiponectin level as a diagnostic marker of metabolic syndrome in obese Japanese children, Hypertens. Res. 28 (2005) 51-57.
9. P.A. Jansson, F. Pellme, A. Hammarstedt, M. Sandqvist, H. Brekke, K. Caidahl, M. Forsberg, R. Volkmann, E. Carvalho, T. Funahashi, Y. Matsuzawa, O. Wiklund, X. Yang, M.R. Taskinen, U. Smith, A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin, FASEB J. 17 (2003) 1434-1440.
10. S.A. Polyzos, J. Kountouras, C. Zavos, E. Tsiaousi, The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease, Diabetes Obes. Metab. 12 (2010) 365-383.
11. D.B. Savage, C.P. Sewter, E.S. Klenk, D.G. Segal, A. Vidal-Puig, R.V. Considine, S. O'Rahilly, Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans, Diabetes 50 (2001) 2199-2202.
12. C.A. Curat, V. Wegner, C. Sengenes, A. Miranville, C. Tonus, R. Busse, A. Bouloumie, Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin, Diabetologia 49 (2006) 744-747.
13. M.Y. Gharibeh, G.M. Al Tawallbeh, M.M. Abboud, A. Radaideh, A.A. Alhader, O.F. Khabour, Correlation of plasma resistin with obesity and insulin resistance in type 2 diabetic patients, Diabetes Metab. 36 (2010) 443-449.
14. N. Sato, K. Kobayashi, T. Inoguchi, N. Sonoda, M. Imamura, N. Sekiguchi, N. Nakashima, H. Nawata, Adenovirus-mediated high expression of resistin causes dyslipidemia in mice, Endocrinology 146 (2005) 273-279.
15. R.R. Banerjee, S.M. Rangwala, J.S. Shapiro, A.S. Rich, B. Rhoades, Y. Qi, J. Wang, M.W. Rajala, A. Pocai, P.E. Scherer, C.M. Steppan, R.S. Ahima, S. Obici, L. Rossetti, M.A. Lazar, Regulation of fasted blood glucose by resistin, Science 303 (2004) 1195-1198.
16. E.D. Muse, S. Obici, S. Bhanot, B.P. Monia, R.A. McKay, M.W. Rajala, P.E. Scherer, L. Rossetti, Role of resistin in diet-induced hepatic insulin resistance, J. Clin. Invest. 114 (2004) 232-239.
17. Y. Qi, Z. Nie, Y.S. Lee, N.S. Singhal, P.E. Scherer, M.A. Lazar, R.S. Ahima, Loss of resistin improves glucose homeostasis in leptin deficiency, Diabetes 55 (2006) 3083-3090.
18. N.S. Singhal, R.T. Patel, Y. Qi, Y.S. Lee, R.S. Ahima, Loss of resistin ameliorates hyperlipidemia and hepatic steatosis in leptin-deficient mice, Am. J. Physiol. Endocrinol. Metab. 295 (2008) E331-338.
19. Y. Makino-Wakagi, Y. Yoshimura, Y. Uzawa, N. Zaima, T. Moriyama, Y. Kawamura, Ellagic acid in pomegranate suppresses resistin secretion by a novel regulatory mechanism involving the degradation of intracellular resistin protein in adipocytes, Biochem. Biophys. Res. Commun. 417 (2012) 880-885.
20. J.H. Lee, J.V. Johnson, S.T. Talcott, Identification of ellagic acid conjugates and other polyphenolics in muscadine grapes by HPLC-ESI-MS, J. Agric. Food Chem. 53 (2005) 6003-6010.
21. S.S. Vasudev, F.J. Ahmad, R.K. Khar, A. Bhatnagar, Y.T. Kamal, S. Talegaonkar, Z. Iqbal, Validated HPLC method for the simultaneous determination of taxol and ellagic acid in a Punica granatum fruit extract containing combination formulation, Pharmazie 67 (2012) 834-838.
22. L. Vanella, I. Barbagallo, R. Acquaviva, C. Di Giacomo, V. Cardile, N.G. Abraham, V. Sorrenti, Ellagic acid: cytodifferentiating and antiproliferative effects in human prostatic cancer cell lines, Curr. Pharm. Des. (2012).
23. N. Wang, Z.Y. Wang, S.L. Mo, T.Y. Loo, D.M. Wang, H.B. Luo, D.P. Yang, Y.L. Chen, J.G. Shen, J.P. Chen, Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer, Breast Cancer Res. Treat. 134 (2012) 943-955.
24. A. Yuce, A. Atessahin, A.O. Ceribasi, M. Aksakal, Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats, Basic Clin. Pharmacol. Toxicol. 101 (2007) 345-349.
25. C. Girish, S.C. Pradhan, Hepatoprotective activities of picroliv, curcumin, and ellagic acid compared to silymarin on carbon-tetrachloride-induced liver toxicity in mice, J. Pharmacol. Pharmacother. 3 (2012) 149-155.
26. S.K. Panchal, L. Ward, L. Brown, Ellagic acid attenuates high-carbohydrate, high-fat diet-induced metabolic syndrome in rats, Eur. J. Nutr. 52 (2013) 559-568.
27. E.G. Bligh, W.J. Dyer, A rapid method of total lipid extraction and purification, Can. J. Biochem. Physiol. 37 (1959) 911-917.
28. C.M. Steppan, S.T. Bailey, S. Bhat, E.J. Brown, R.R. Banerjee, C.M. Wright, H.R. Patel, R.S. Ahima, M.A. Lazar, The hormone resistin links obesity to diabetes, Nature 409 (2001) 307-312.
29. Y. Yang, J.Y. Shin, J.M. Oh, C.H. Jung, Y. Hwang, S. Kim, J.S. Kim, K.J. Yoon, J.Y. Ryu, J. Shin, J.S. Hwang, T.Y. Yoon, Y.K. Shin, D.H. Kweon, Dissection of SNARE-driven membrane fusion and neuroexocytosis by wedging small hydrophobic molecules into the SNARE zipper, Proc. Natl. Acad. Sci. USA 107 (2010) 22145-22150.
30. J. Costandi, M. Melone, A. Zhao, S. Rashid, Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling, Circ. Res. 108 (2011) 727-742.
31. M. Melone, L. Wilsie, O. Palyha, A. Strack, S. Rashid, Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9, J. Am. Coll. Cardiol. 59 (2012) 1697-1705.
32. L. Zhou, X. Yu, Q. Meng, H. Li, C. Niu, Y. Jiang, Y. Cai, M. Li, Q. Li, C. An, L. Shu, A. Chen, H. Su, Y. Tang, S. Yin, S. Raschke, K. Eckardt, J. Eckel, Z. Yang, Resistin reduces mitochondria and induces hepatic steatosis in mice by the protein kinase C/protein kinase G/p65/PPAR gamma coactivator 1 alpha pathway, Hepatology (2012).
33. J. Ren, L. Pulakat, A. Whaley-Connell, J.R. Sowers, Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease, J. Mol. Med. (Berl.) 88 (2010) 993-1001.
34. Y.I. Kim, S. Hirai, T. Goto, C. Ohyane, H. Takahashi, T. Tsugane, C. Konishi, T. Fujii, S. Inai, Y. Iijima, K. Aoki, D. Shibata, N. Takahashi, T. Kawada, Potent PPARalpha activator derived from tomato juice, 13-oxo-9,11-octadecadienoic acid, decreases plasma and hepatic triglyceride in obese diabetic mice, PLoS ONE 7 (2012) e31317.